

**21-JUL-2017 18:11**  
**OPEN STUDIES IRB REPORT**

<u>Disease Site</u>	<u>Study</u>	<u>Study Name</u>	<u>Open Date</u>	<u>Number of Active Institutions</u>	<u>Number of Current IRBs</u>
BREAST	S1007	Breast,Adj,N1,Endocrine+/-Chemo	15-JAN-11	408	206
	S1207	Brst,Adj,Endocrine+/-Everolimus	03-SEP-13	485	248
	S1416	Brst, TNBC/BRCA, Cis+/- ABT-888	07-JUL-16	267	124
	S1418	Breast, Adj, TNBC, MK-3475 (Pembrolizumab)	15-NOV-16	366	149
	A011106	Breast, Neoadj, ALTERNATE study	15-FEB-14	267	126
	A011203	Breast, Adv, Tam vs Endoxifen	27-JAN-15	242	90
	A011401	Breast, adj, Stage II/III HER2-, weight loss	29-AUG-16	261	147
	B55	Brst, Adj Olaparib for BRCA,TNBC	03-JUL-14	422	194
	E1Z11	Brst,Genetic Predictors of AIMSS	10-MAY-13	270	95
	E2112	Brst,Adv,Exemestane+/-Entinostat	02-JAN-14	296	165
	NRGBR003	Brst,Adj,TNBC,AC -> WP +/- Carbo	22-JAN-15	441	217
Breast	A011502	Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo	08-DEC-16	0	180
CCD	S1415CD	TrACER CSF Standing Order Intervention for FN	01-SEP-16	52	67
	S1417CD	Colorectal, Cost Cohort Study	13-MAY-16	199	57
	A011104	Preoperative Breast MRI	21-FEB-14	176	64
ERLYTX	S1609	Rare Tumor, Comb Nivo/Ipi	13-JAN-17	324	132
	A071102	GBM, adj TMZ +/- Veliparib	19-SEP-14	361	161
	A071401	Prog Meningiomas,SMO/AKT/NF2 Inhib	06-AUG-15	234	102
	ARST1321	NonRhabdo STS,Pazopanib (PAZNTIS)	16-MAY-14	254	121
	EAY131	MATCH	12-AUG-15	436	230
GI	S1505	Panc,Resect, Perioperative Chemo	12-OCT-15	291	112
	S1513	Panc, Met, FOLFIRI vs mFOLFIRI + ABT-888	01-SEP-16	301	132
	A021501	Adeno Panc,Borderline Resect,Chemo vs ChemoRT	01-DEC-16	0	13
	E7208	CRC,Adv, Irino/Cet+/-Ramucirumab	20-FEB-14	203	87
	EA2133	Anal, local recur/met, Cis+5FU vs Taxol/Carbo	29-JAN-16	0	32
	EA2142	GI NEC, Adv G3, EP vs TMZ + CAP	06-NOV-15	185	70
	N1048	Rectal,LocalAdv,ChemoRT+/-FOLFOX	13-JAN-12	0	167
	NRGGI002	Rectal, Ph II, Sensitization using TNT	12-OCT-16	267	114
	R0848	Panc, Adj, Erlotinib v ChemoRT	01-MAR-14	0	146
GU	S1314	Blad, COXEN Neoadj. Chemo + Cyst	11-JUL-14	214	111
	S1500	pRCC,Adv, Sunitinib vs MET inhib	05-APR-16	197	84
	S1602	Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG	07-FEB-17	127	50

21-JUL-2017 18:11  
OPEN STUDIES IRB REPORT

18:10 Friday, July 21, 2017 2

Disease Site	Study	Study Name	Open Date	Number of Active Institutions	Number of Current IRBs
	S1605	Blad, BCG-Unresponsive NMIBC, Atezolizumab	07-FEB-17	98	48
	A031102	GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE)	01-JUL-15	43	30
	E2810	Renal, Pazopanib vs Placebo	17-APR-12	187	90
	EA8141	UTUC, HG, Chemo then Surg	27-JAN-15	161	77
	R0924	Pros, NADT+WPRT vs. NADT+P&SV RT	07-JUL-11	0	157
LEUK	S1312	ALL, CD22+, REL/REF, Inotuzumab+CVP	01-APR-14	4	5
	S1318	ALL, Age 65+, Ph±, Blinatumomab	12-JAN-15	177	70
	S0919	Rel AML: Pravastatin+Ida+Ara-C	15-AUG-09	86	28
	E1910	BCR-ABL-neg, B ALL, Blinatumomab	23-DEC-13	167	87
	E2906	AML, Age 60+, Clo vs Dauno+Cy	24-FEB-11	154	78
	NHLBIMDS	LEUK, National MDS Study	05-APR-16	57	23
LUNG	S1400	SCCA,Adv, Biomarker Master	15-JUN-14	437	222
	S1400G	HRRD: Talazoparib (BMN 673)	07-FEB-17	434	216
	S1400I	Non-Match: Nivo + Ipi vs Nivo	18-DEC-15	437	221
	S1403	Adv,EGFR-mt,Afatinib+/-Cetuximab	25-MAR-15	227	92
	8811	NSCLC, Stage III,ChemoRT+ABT-888	02-JAN-13	144	51
	A081105	ALCHEMIST1, EGFR mut, Erlotinib	02-JAN-14	0	253
	A151216	ALCHEMIST0 - screening	06-FEB-14	461	253
	C140503	NSCL, Lobect v Sublobar resect	09-JUL-07	104	53
	C30610	SCLC, Thoracic RT	21-MAR-08	244	114
	E4512	ALCHEMIST2, ALK mut, Crizotinib	18-AUG-14	465	252
	EA5142	ALCHEMIST3, Non-match, Nivolumab	16-MAY-16	443	234
	NRGCC003	SCLC, PCI or HA-PCI	07-DEC-15	324	137
	R1306	NSCLC,Adv,ALK/EGFR,TargetAgents	04-NOV-13	157	69
LYMPH	A051301	ABC DLBCL, Auto HCT and Ibrutinib/Placebo	15-JUL-16	120	49
MELAN	S1320	Adv, BRAF mut, Inter v Contin	22-JUL-14	243	104
	S1404	Melan, Adv, HD-IFN/Ipilimumab vs MK-3475	15-OCT-15	413	175
	S1512	Melan, Adv, Desmoplastic, MK-3475 (pembro)	20-OCT-16	62	26
	EA6134	Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T	15-DEC-15	338	140
	EA6141	Melan, Avd, Nivolumab+Ipi ± Sargmostim	01-MAR-16	298	120
MMYEL	E1A11	MM, frontline, BLD vs CLD	22-NOV-13	299	129
	E3A06	AMM, Lenalidomide vs Observation	08-NOV-10	272	125

21-JUL-2017 18:11  
OPEN STUDIES IRB REPORT

Disease Site	Study	Study Name	Open Date	Number of Active Institutions	Number of Current IRBs	
OTHER	A091202	Sarc, Efatutazone vs Placebo, Unresect ,Lipo	02-SEP-14	54	30	
	A091304	Adv Sarc, MLN0128 v Pazopanib, Phi/II	26-JAN-15	179	64	
	A091305	HN, Adv, Thyroid PPAR agonist + Chemo	01-SEP-14	93	30	
	A091401	Sarc,	18-JUN-15	199	78	
	A091404	HN, AR+, Enzalutamide	25-SEP-15	42	13	
	AOST1521	Osteo CDX-011 in Rec/Ref Dz,Ph 2	02-JUL-15	46	32	
	E3311	Oroph,Srg + Low or Std IMRT	01-MAR-14	193	70	
	EA3132	HN SCC, Stg III-IV , Adj RT +/- Cisp	29-MAR-16	0	6	
	EAQ152	Communication & education in tumor profiling	26-SEP-16	168	81	
	G0281	Ovar, Recur/prog LG, IC chemo vs trametinib	27-FEB-14	0	17	
	NRGBN001	HN, novel vs. std chemoradiation + chemo	28-AUG-15	0	98	
	NRGGY004	Ovar, Recur HG, VEGFi vs VEGFi+PARPi vs chemo	04-FEB-16	340	153	
	NRGGY005	OVAR, Cedir vs Olaparib vs C+O vs Std of Care	06-FEB-16	143	64	
	NRGHN001	Nasopharyngeal , Individual Tx EBV	21-APR-14	192	68	
	NRGHN002	HN, Adv, Orophyx RT vs RT+ Chemo	27-OCT-14	287	104	
	R0724	Cervical, Chem+RT +/- Adj. Chemo	15-JAN-14	247	98	
	R0920	HN, Adv, Postop IMRT ± Cetuximab	24-DEC-13	356	157	
	R1216	HN, Adv,Cis vs Dtx vs Dtx+Cetux	18-MAR-13	279	121	
	PREV	S0820	PACES: ColrecStg0-3 Blind DFMO/Sulindac	01-MAR-13	323	117
		A211102	Breast, Atypia via RPFNA, Metformin v Placebo	01-FEB-15	29	7
A211201		Breast Density, MA.32 companion	22-AUG-12	21	12	
EA1141		Breast, Abbrev. MRI vs Digital Tomosynthesis	02-SEP-16	0	5	
SURV	S1316	Compar. Effectiv. Trial for MBO	09-MAR-15	13	15	
	E1Q11	EROS: Reproductive Health in Cancer Survivors	30-SEP-15	0	35	
SXQOL	A221101	Glioma, Nuvigil/Placebo Fatigue	03-JUN-13	216	91	
	A221102	Brst,Al Arthralgia,Testosterone	07-SEP-12	0	64	